Eyenovia, Inc. Prices Public Offering of Common Stock
July 11 2019 - 9:00AM
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print technology, today
announced the pricing of an underwritten public offering of
4,388,490 shares of its common stock at a price to the public of
$2.78 per share. In addition, Eyenovia has granted the underwriters
a 30-day option to purchase up to 658,273 additional shares of
common stock at the public offering price, less underwriting
discounts and commissions. The offering is expected to close on
July 15, 2019, subject to customary closing conditions.
The gross proceeds to Eyenovia from the public
offering, before deducting underwriting discounts and commissions
and offering expenses payable by Eyenovia, are expected to be
approximately $12.2 million. Eyenovia intends to use the net
proceeds from the public offering, together with other available
funds, for the MicroProst and MicroPine clinical studies and for
working capital and general corporate purposes.
Oppenheimer & Co. Inc. is acting as the sole
book-running manager for the offering. Ladenburg Thalmann & Co.
Inc. is acting as the lead manager for the offering. National
Securities Corporation is acting as the co-manager for the
offering.
The offering is being made pursuant to a shelf
registration statement on Form S-3 (File No. 333-229365) that was
declared effective by the Securities and Exchange Commission (the
“SEC”) on February 12, 2019. A preliminary prospectus supplement
related to the offering has been filed with the SEC and a final
prospectus supplement related to the offering will be filed
with the SEC and will be available on the SEC’s website, located at
www.sec.gov. Copies of the prospectus supplement and the
accompanying prospectus relating to the offering may also be
obtained from Oppenheimer & Co. Inc., Attention: Syndicate
Prospectus Department, 85 Broad Street, 26th Floor, New York, NY,
10004, by telephone at (212) 667-8055, or by email at
EquityProspectus@opco.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities nor
shall there be any offer or sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print technology.
Eyenovia’s pipeline is currently focused on the late-stage
development of microdosed medications for mydriasis, myopia
progression, glaucoma and other eye diseases.
Forward-Looking
StatementsExcept for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions or any
other statements relating to our future activities or other future
events or conditions. These statements are based on current
expectations, estimates and projections about our business based,
in part, on assumptions made by management. These statements are
not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and are likely to,
differ materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors discussed from
time to time in documents which we file with the SEC. In addition,
such statements could be affected by risks and uncertainties
related to, among other things, the Company’s expectations
regarding the closing of the public offering, its anticipated use
of net proceeds from the public offering, its need to raise
additional capital even after this financing, and other risks and
uncertainties described in Eyenovia’s filings with the SEC. Any
forward-looking statements speak only as of the date on which they
are made, and except as may be required under applicable securities
laws, Eyenovia does not undertake any obligation to update any
forward-looking statements.
Company Contact:Eyenovia, Inc.
John GandolfoChief Financial Officerjgandolfo@eyenoviabio.com
Investor Contact:The Ruth
GroupTram Bui / Alexander LoboPhone:
646-536-7035/7037tbui@theruthgroup.com / alobo@theruthgroup.com
Media Contact:The Ruth
GroupKirsten Thomas508-280-6592kthomas@theruthgroup.com
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Sep 2023 to Sep 2024